1. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic Fatigue Syndrome: A Working Case Definition. Ann Intern Med 1988; 108: 387-9.

2. Fukuda K, Straus SE, Hickie I, et al, and the International Chronic Fatigue Syndrome Study Group. Chronic Fatigue Syndrome: a comprehensive approach to its definition and study. Ann Intern Med 1994;121:953-9.

3. Sharpe MC, Archard LC, Banatvala JE, et al. A report – chronic fatigue syndrome: guidelines for research. J Roy Soc of Med 1991;84: 118-21.

4. Carruthers BM, Jain AK, De Meirleir KL, et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols. J Chronic Fatigue Syndr 2003;11(1):7-115.

5. Reyes M, Nisenbaum R, Hoaglin DC, et al. Prevalence and Incidence of Chronic Fatigue Syndrome in Wichita, Kansas. Arch Intern Med 2003;163:1530-6.

6. Jason LA, Richman JA, Rademaker AW, et al. A Community-Based Study of Chronic Fatigue Syndrome. Arch Intern Med 1999;159:2129-37.

7. Reeves WC, Jones JF, Maloney E, et al. Prevalence of Chronic Fatigue Syndrome in Metropolitan, Urban and Rural Georgia. Pop Health Metr 2007;5:5.

8. Kato K, Sullivan PF, Evengård B, et al. Premorbid Predictors of Chronic Fatigue. Arch Gen Psych 2006;63:1267-72.

9. Heim C, Wagner D, Maloney E, et al. Early Adverse Experience and Risk for Chronic Fatigue Syndrome. Results From a Population-Based Study. Arch Gen Psych 2006;63:1258-66.

10. Whiting P, Bagnall A-M, Sowden AJ, et al. Interventions for the Treatment and Management of Chronic Fatigue Syndrome. JAMA 2001;286:1360-8.

11. Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue and chronic fatigue syndrome: a systematic review. Q J Med 1997;90:223-33.

12. White PD, Thomas JM, Amessis J, et al. The existence of a fatigue syndrome after glandular fever. Psychol Med 1995;25:907-16.

13. Smith WR, Noonan C, Buchwald D. Mortality in a cohort of chronically fatigued patients. Psychol Med 2006;36:1301-6.

14. Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997;4:134-53.

15. Ablashi DV. Viral studies of CFS. Clin Infect Dis 1994;18:130-2.

16. Hotopf MH, Wessely S. Viruses, neurosis and fatigue. J Psychosom Res 1994;38:499-514.

17. Komaroff AL, Fagioli LR, Geiger AM, et al. An examination of the working case definition of chronic fatigue syndrome. Am J Med 1996;100:56-64.

18. Wessely S, Butler S, Chalder T, et al. The cognitive behavioural management of the post-viral fatigue syndrome. In R. Jenkins and J. Mowbrey (Eds.), Postviral fatigue syndrome (pp.305-334). Chichester: John Wiley and Sons.

19. Surawy C, Hackmann A, Hawton K, et al. Chronic fatigue syndrome: a cognitive approach. Behaviour Research Therapy 1995;33:535-44.

20. White C, Schwitzer R. The role of personality in the development and perpetuation of chronic fatigue syndrome. J Psychosomatic Med 2000;48:515-24.

21. Heim C, Ehlert V, Hellhammer DH. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology 2000;25:1-35.

22. Tsigos C, Chrousos GP. Physiology of the hypothalamic-pituitary-adrenal axis in health and dysregulation in psychiatric and autoimmune disorders. Endocrinol Metab Clin Nth Am 1994;23:451-66.

23. Munck A, Guyre PM, Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to physiological actions. Endocr Rev 1984;5:25-44.

24. Pratt WB. Glucocorticoid receptor structure and the initial events in signal transduction. Prog Clin Biol Res 1990;322:119-32.

25. Scheinman RI, Gualberto A, Jewell CM, et al. Characterisation of mechanisms involved in transrepression of NF-KB by activated glucocorticoid receptors. Mol Cell Biol 1995;15:943-53.

26. van Rossum EFC and Lamberts SWJ. Glucocorticoid resistance syndrome: a diagnostic and therapeutic approach. Best Pract Res Clin Endocrinol Metab 2006;20:611-26.

27. Bronnegard M, Werner S, Gustafsson JA. Primary cortisol resistance associated with a thermolabile glucocorticoid receptor in a patient with fatigue as the only symptom. J Clin Invest 1989;78:1270-8.

28. Huizenga N, De Lange P, Koper JW, et al. Five Patients with Biochemical and/or Clinical Generalised Glucocorticoid Resistance without Alterations in the Glucocorticoid Receptor Gene. J Clin Endocrinol Metab 2000;85:2076-81.

29. Rajeevan MS, Smith AK, Dimulescu I, et al. Glucocorticoid receptor polymorphisms and haplotypes associated with chronic fatigue syndrome. Genes, Brain and Behav 2007;6:167-76.

30. Hammond GL. Molecular properties of corticosteroid binding globulin and the sex-steroid binding proteins. Endocr Rev 1990;11:65-79.

31. Lewis JG, Bagley CJ, Elder PA, et al. Plasma free cortisol fraction reflects levels of functioning corticosteroid-binding globulin. Clinica Chimica Acta 2005;359:189-94.

32. Hammond GL, Smith CL, Paterson NA, et al. A role for corticosteroid-binding globulin in delivery of cortisol to activated neutrophils. J Clin Endocrinol Metab 1990;71:34-9.

33. Ballard PL. Delivery and transport of glucocorticoids to target cells. Monographs on Endocrinology 1979;12:25-48.

34. Ho JT, Al-Musalhi H, Chapman MJ, et al. Septic shock and sepsis: a comparison of total and free plasma cortisol levels. J Clin Endocrinol Metab 2006;91:105-14.

35. Papanicolaou DA, Wilder RL, Manolagas SC, et al. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127-37.

36. Tsigos C, Kyrou I, Chrousos GP, et al. Prolonged suppression of corticosteroid-binding globulin by recombinant human interleukin-6 in man. J Clin Endocrinol Metab 1998;83:3379.

37. Bernier J, Jobin N, Emptoz-Bonneton A, et al. Decreased corticosteroid-binding globulin in burn patients: relationship with interleukin-6 and fat in nutritional support. Crit Care Med 1998;26:452-60.

38. Schlechte JA, Hamilton D. The effects of glucocorticoids on corticosteroid binding globulin. Clin Endocrinol (Oxf) 1987; 27: 197-203.

39. Cole TJ, Harris HJ, Hoong I, et al. The glucocorticoid receptor is essential for maintaining basal and dexamethasone-induced repression of the murine corticosteroid-binding globulin gene. Mol Cell Endocrinol 1999;154:29-36.

40. Emptoz-Bonneton A, Cousin P, Seguchi K, et al. Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab 2000;85:361-7.

41. Brunner E, Baima J, Vieira TC, et al. Hereditary corticosteroid-binding globulin deficiency due to a missense mutation (Asp367Asn, CBG Lyon) in a Brazilian kindred. Clin Endocrinol 2003;58:756-62.

42. Torpy DJ, Bachmann AW, Grice JE, et al. Familial Corticosteroid-Binding Globulin Deficiency Due to a Novel Null Mutation: Association with Fatigue and Relative Hypotension. J Clin Endocrinol Metab 2001;86:3692-700.

43. Torpy DJ, Bachmann AW, Gartside M, et al. Association between chronic fatigue syndrome and the corticosteroid-binding globulin gene ALA SER224 polymorphism. Endocr Res 2004;30:417-29.

44. Smith CL, Power SG and Hammond GL. A Leu-His substitution at residue 93 in human corticosteroid binding globulin results in reduced affinity for cortisol. J Steroid Biochem Mol Biol 1992;42:671-6.

45. Torpy DJ and Ho JT. Corticosteroid-binding globulin gene polymorphisms: clinical implications and links to idiopathic chronic fatigue disorders. Clin Endocrinol 2007, epub ahead of print.

46. Cleare AJ. The Neuroendocrinology of Chronic Fatigue Syndrome. Endocr Rev 2003;24:236-52.

47. Cleare AJ, Blair D, Chambers S, et al. Urinary free cortisol in Chronic Fatigue Syndrome. Am J Psych 2001;158:641-3.

48. Jerjes WK, Taylor NF, Peters TJ, et al. Urinary cortisol and cortisol metabolite excretion in chronic fatigue syndrome. Psychosom Med 2006;68:578-82.

49. Crofford, LJ, Young EA, Engleberg NC, et al. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain, Behav Immun 2004;18:314-25.

50. Jerjes WK, Peters TJ, Taylor NF, et al. Diurnal excretion of urinary cortisol, cortisone and cortisol metabolites in chronic fatigue syndrome. J Psychosom Res 2006;60:145-53.

51. DiGiorgio A, Hudson M, Jerjes W, et al. 24-hour pituitary and adrenal hormone profiles in chronic fatigue syndrome. Psychosom Med 2005;67:433-40.

52. Jerjes WK, Cleare AJ, Wessely S, et al. Diurnal patterns of salivary cortisol and cortisone output in chronic fatigue syndrome. J Affect Disord 2005;87:299-304.

53. Strickland P, Morriss R, Wearden A, et al. A comparison of salivary cortisol in chronic fatigue syndrome, community depression and healthy controls. J Affect Disord 1998;47:191-4.

54. Roberts ADL, Wessely S, Chalder T, et al. Salivary cortisol response to awakening in chronic fatigue syndrome. Br J Psych 2004;184:136-41.

55. Scott LV, Salahuddin F, Cooney J, et al. Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health. J Affect Disord 1999;52:129-37.

56. Scott LV, The J, Reznek R, et al. Small adrenal glands in chronic fatigue syndrome: a preliminary computed tomography study. Psychoneuroendocrinology 1999;24:759-68.

57. Cleare AJ, O’Keane V, Miell JP. Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome. Psychoneuroendocrinology 2004;29:724-32.

58. Cleare AJ, Miell J, Heap E, et al. Hypothalamo-Pituitary-Adrenal Axis Dysfunction in Chronic Fatigue Syndrome, and the Effects of Low-Dose Hydrocortisone Therapy. J Clin Endocrinol Metab 2001;86:3545-54.

59. Scott LV, Medbak S, Dinan TG. Blunted adrenocorticotropin and cortisol responses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome. Acta Psychiatr Scand 1998;97:450-7.

60. Inder WJ, Prickett TCR, Mulder RT. Normal opioid tone and hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome despite marked functional impairment. Clin Endocrinol 2005;62:343-8.

61. Bearn J, ALlain T, Coskeran P, et al. Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycaemia in chronic fatigue syndrome. Biol Psychiatry 1995;37:245-52.

62. Scott LV, Burnett F, Medbaks S, et al. Naloxone-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome. Psychol Med 1998;28:285-93.

63. Jerjes WK, Taylor NF, Wood PJ, et al. Enhanced feedback sensitivity to prednisolone in chronic fatigue syndrome. Psychoneuroendocrinology 2007;32:192-8.

64. Cleare AJ, Heap E, Malhi GS, et al. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet 1999;353:455-8.

65. McKenzie R, O’Fallon A, Dale J, et al. Low-Dose Hydrocortisone for Treatment of Chronic Fatigue Syndrome. A randomised controlled trial. JAMA 1998;280:1061-6.

66. Peterson PK, Pheley A, Schroeppel J, et al. A preliminary placebo-controlled trial of fludrocortisone for chronic fatigue syndrome. Arch Intern Med 1998;158:908-14.

67. Blockmans D, Persoons P, Van Houdenhove B, et al. Combination Therapy with Hydrocortisone and Fludrocortisone Does Not Improve Symptoms in Chronic Fatigue Syndrome: A Randomised Placebo-Controlled, Double-blind Crossover Study. Am J Med 2003;114:736-41.